Arvin K. George, MD

The 510(k) clearance was supported by 12-month data from the VAPOR 2 trial, which were presented at the 2025 SUO Annual Meeting.

The PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.

“It's really a reapplication of the existing technology for BPH that is familiar to many of us already and we use in our clinical practices,” says Arvin K. George, MD.

“I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly changed into optimism,” says Arvin K. George, MD.